Material Event (Form 8-K)

Item 8.01 Other Events.

Nuvalent, Inc. (the "Company" or "Nuvalent") is aware of the announcement this morning by Royalty Pharma plc ("Royalty Pharma") that it has acquired a preexisting royalty interest in Nuvalent's neladalkib and zidesamtinib investigational product candidates from an undisclosed third party for up to $315 million. Information regarding Nuvalent's revenue share agreement with its scientific founder is available in Note 10 of Nuvalent's financial statements contained in Nuvalent's Annual Report on Form 10-K for the year ended December 31, 2024, and elsewhere in the Company's filings with the Securities and Exchange Commission. The "low single digit preexisting royalty" referred to in the Royalty Pharma press release is 1.5% of net sales of both neladalkib and zidesamtinib.